Clinical Scorecard: Association of Erythrocyte Odd-Chain Fatty Acids with Cardiometabolic Disease Risk: A Prospective Analysis and Updated Meta-Study
At a Glance
Category
Detail
Condition
Cardiometabolic diseases including ischemic heart disease, diabetes, and stroke
Key Mechanisms
Inverse associations of erythrocyte odd-chain fatty acids (OCFAs) 15:0 and 17:0 with incident cardiometabolic diseases; OCFAs as biomarkers reflecting dietary intake of dairy, fish/seafood, and dietary fiber
Target Population
Asian adults, specifically Chinese adults aged 30–79 years with varying dairy intake
Care Setting
Population-based epidemiological and nutritional assessment settings
Key Highlights
Erythrocyte OCFAs 15:0 and 17:0 inversely associated with incident ischemic heart disease and diabetes in Chinese adults.
OCFAs correlated with dietary intake of dairy products, wheat and coarse grains, and fish/seafood in Asian populations with low dairy consumption.
Meta-analysis supports universal applicability of OCFAs as biomarkers for cardiometabolic disease risk across diverse populations.
Guideline-Based Recommendations
Diagnosis
Consider measuring erythrocyte 15:0 and 17:0 levels as biomarkers for dietary intake and cardiometabolic risk stratification.
Management
Promote dietary sources rich in OCFAs such as dairy, fish/seafood, and dietary fiber to potentially reduce cardiometabolic disease risk.
Use OCFA levels to guide personalized nutrition interventions aimed at mitigating cardiometabolic disease risks.
Monitoring & Follow-up
Monitor erythrocyte OCFA levels to assess adherence to dietary interventions and evaluate cardiometabolic risk changes over time.
Risks
Low levels of erythrocyte 15:0 and 17:0 may indicate higher risk for ischemic heart disease and diabetes.
Patient & Prescribing Data
Asian adults with varying dairy intake and risk factors for cardiometabolic diseases
Increasing dietary intake of OCFA-rich foods may serve as a modifiable strategy to lower cardiometabolic disease risk; erythrocyte OCFA levels can serve as objective biomarkers to tailor and monitor nutritional interventions.
Clinical Best Practices
Incorporate erythrocyte OCFA measurement in nutritional assessments for cardiometabolic risk evaluation.
Advocate for diverse dietary sources of OCFAs beyond dairy, including fish/seafood and dietary fiber, especially in populations with low dairy consumption.
Use OCFA biomarker data to personalize dietary recommendations and monitor intervention efficacy in reducing cardiometabolic disease incidence.
